The voltage-gated sodium channel Na(v)1.7 associated with endometrial cancer

Background: Endometrial cancer is the most common gynecologic malignancy in women in the developed countries. Despite recent progress in functional characterization of voltage-gated sodium channel (Na(v)) in multiple cancers, very little was known about the expression of Na(v) in human endometrial cancer. The present study sought to determine the role of Na(v) and molecular nature of this channel in the endometrial cancer. Methods: PCR approach was introduced to determine expression level of Na(v) subunits in endometrial cancer specimens. Pharmacological agents were used to investigate Na(v) function in endometrial cancer cells. Flow cytometry were used to test cancer apoptosis, and invasion assays were applied to test tumor metastasis. Results: Transcriptional levels of the all Na(v) α and β subunits were determined by real time-PCR in endometrial cancer with pair tissues of carcinoma and adjacent nonneoplastic tissue, Na(v)1.7 was the most highly expressed Na(v) subtype in endometrial cancer tissues. Na(v)1.7 level was closely associated with tumor size, local lymph node metastasis, and 5-year and 10-year survival ratio. Inhibition of this channel by Na(v)1.7 blocker PF-05089771, promoted cancer apoptosis and attenuated cancer cell invasion. Conclusion: These results establish a relationship between voltage-gated sodium channel protein and endometrial cancer, and suggest that Na(v)1.7 is a potential prognostic biomarker and could serve as a novel therapeutic target for endometrial cancer.